Cargando…
High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma
BACKGROUND: Cathepsin E (CTSE), an aspartic proteinase, is differentially expressed in the metaplasia–dysplasia–neoplasia sequence of gastric and colon cancer. We evaluated CTSE in Barrett’s esophagus (BE) and cancer because increased CTSE levels are linked to improved survival in several cancers, a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458267/ https://www.ncbi.nlm.nih.gov/pubmed/25348778 http://dx.doi.org/10.1245/s10434-014-4155-y |
_version_ | 1782375062507094016 |
---|---|
author | Fisher, Oliver M. Levert-Mignon, Angelique J. Lord, Sarah J. Botelho, Natalia K. Freeman, Araluen K. Thomas, Melissa L. Falkenback, Dan Wettstein, Antony Whiteman, David C. Bobryshev, Yuri V. Lord, Reginald V. |
author_facet | Fisher, Oliver M. Levert-Mignon, Angelique J. Lord, Sarah J. Botelho, Natalia K. Freeman, Araluen K. Thomas, Melissa L. Falkenback, Dan Wettstein, Antony Whiteman, David C. Bobryshev, Yuri V. Lord, Reginald V. |
author_sort | Fisher, Oliver M. |
collection | PubMed |
description | BACKGROUND: Cathepsin E (CTSE), an aspartic proteinase, is differentially expressed in the metaplasia–dysplasia–neoplasia sequence of gastric and colon cancer. We evaluated CTSE in Barrett’s esophagus (BE) and cancer because increased CTSE levels are linked to improved survival in several cancers, and other cathepsins are up-regulated in BE and esophageal adenocarcinoma (EAC). METHODS: A total of 273 pretreatment tissues from 199 patients were analyzed [31 normal squamous esophagus (NE), 29 BE intestinal metaplasia, 31 BE with dysplasia (BE/D), 108 EAC]. CTSE relative mRNA expression was measured by real-time polymerase chain reaction, and protein expression was measured by immunohistochemistry. CTSE serum levels were determined by enzyme-linked immunosorbent assay. RESULTS: Median CTSE mRNA expression levels were ≥1,000-fold higher in BE/intestinal metaplasia and BE/D compared to NE. CTSE levels were significantly lower in EAC compared to BE/intestinal metaplasia and BE/D, but significantly higher than NE levels. A similar expression pattern was present in immunohistochemistry, with absent staining in NE, intense staining in intestinal metaplasia and dysplasia, and less intense EAC staining. CTSE serum analysis did not discriminate patient groups. In a uni- and multivariable Cox proportional hazards model, CTSE expression was not significantly associated with survival in patients with EAC, although CTSE expression above the 25th percentile was associated with a 41 % relative risk reduction for death (hazard ratio 0.59, 95 % confidence interval 0.27–1.26, p = 0.17). CONCLUSIONS: CTSE mRNA expression is up-regulated more than any known gene in Barrett intestinal metaplasia and dysplasia tissues. Protein expression is similarly highly intense in intestinal metaplasia and dysplasia tissues. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-014-4155-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4458267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-44582672015-06-11 High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma Fisher, Oliver M. Levert-Mignon, Angelique J. Lord, Sarah J. Botelho, Natalia K. Freeman, Araluen K. Thomas, Melissa L. Falkenback, Dan Wettstein, Antony Whiteman, David C. Bobryshev, Yuri V. Lord, Reginald V. Ann Surg Oncol Translational Research and Biomarkers BACKGROUND: Cathepsin E (CTSE), an aspartic proteinase, is differentially expressed in the metaplasia–dysplasia–neoplasia sequence of gastric and colon cancer. We evaluated CTSE in Barrett’s esophagus (BE) and cancer because increased CTSE levels are linked to improved survival in several cancers, and other cathepsins are up-regulated in BE and esophageal adenocarcinoma (EAC). METHODS: A total of 273 pretreatment tissues from 199 patients were analyzed [31 normal squamous esophagus (NE), 29 BE intestinal metaplasia, 31 BE with dysplasia (BE/D), 108 EAC]. CTSE relative mRNA expression was measured by real-time polymerase chain reaction, and protein expression was measured by immunohistochemistry. CTSE serum levels were determined by enzyme-linked immunosorbent assay. RESULTS: Median CTSE mRNA expression levels were ≥1,000-fold higher in BE/intestinal metaplasia and BE/D compared to NE. CTSE levels were significantly lower in EAC compared to BE/intestinal metaplasia and BE/D, but significantly higher than NE levels. A similar expression pattern was present in immunohistochemistry, with absent staining in NE, intense staining in intestinal metaplasia and dysplasia, and less intense EAC staining. CTSE serum analysis did not discriminate patient groups. In a uni- and multivariable Cox proportional hazards model, CTSE expression was not significantly associated with survival in patients with EAC, although CTSE expression above the 25th percentile was associated with a 41 % relative risk reduction for death (hazard ratio 0.59, 95 % confidence interval 0.27–1.26, p = 0.17). CONCLUSIONS: CTSE mRNA expression is up-regulated more than any known gene in Barrett intestinal metaplasia and dysplasia tissues. Protein expression is similarly highly intense in intestinal metaplasia and dysplasia tissues. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1245/s10434-014-4155-y) contains supplementary material, which is available to authorized users. Springer US 2014-10-28 2015 /pmc/articles/PMC4458267/ /pubmed/25348778 http://dx.doi.org/10.1245/s10434-014-4155-y Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Translational Research and Biomarkers Fisher, Oliver M. Levert-Mignon, Angelique J. Lord, Sarah J. Botelho, Natalia K. Freeman, Araluen K. Thomas, Melissa L. Falkenback, Dan Wettstein, Antony Whiteman, David C. Bobryshev, Yuri V. Lord, Reginald V. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma |
title | High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma |
title_full | High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma |
title_fullStr | High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma |
title_full_unstemmed | High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma |
title_short | High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett’s Esophagus and Adenocarcinoma |
title_sort | high expression of cathepsin e in tissues but not blood of patients with barrett’s esophagus and adenocarcinoma |
topic | Translational Research and Biomarkers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458267/ https://www.ncbi.nlm.nih.gov/pubmed/25348778 http://dx.doi.org/10.1245/s10434-014-4155-y |
work_keys_str_mv | AT fisheroliverm highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT levertmignonangeliquej highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT lordsarahj highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT botelhonataliak highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT freemanaraluenk highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT thomasmelissal highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT falkenbackdan highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT wettsteinantony highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT whitemandavidc highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT bobryshevyuriv highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma AT lordreginaldv highexpressionofcathepsineintissuesbutnotbloodofpatientswithbarrettsesophagusandadenocarcinoma |